<DOC>
	<DOCNO>NCT01859455</DOCNO>
	<brief_summary>This study design investigate safety , tolerability , pharmacokinetics pharmacodynamics LGT209 hypercholesterolemic patient take common statin medication healthy volunteer .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics LGT209 Healthy Volunteers With Elevated Cholesterol Hypercholesterolemic Patients Treated With Statins</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Healthy volunteer : Male female subject 18 70 year age , general good health fast LDLcholesterol &gt; 90 mg/dL fast serum triglyceride &lt; 400 mg/dL Patients statin therapy : Male female patient 18 70 year age receive atorvastatin simvastatin fast LDLcholesterol &gt; 90 mg/dL fast serum triglyceride &lt; 400 mg/dL Healthy volunteer : History hypersensitivity study drug drug similar chemical class Women childbearing potential unless use highly effective method contraception Conditions might impact safety biologic activity study drug Statin patient : Use concomitant medication know impact safe use efficacy atorvastatin simvastatin base drug label Women childbearing potential unless use highly effective method contraception dose least 100 day study drug administration Conditions might impact safety biologic activity study drug Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypercholesterolemia ,</keyword>
	<keyword>LDL cholesterol lowering ,</keyword>
	<keyword>proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) ,</keyword>
	<keyword>LGT209 ,</keyword>
	<keyword>drug safety ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>